hydroxychloroquine - Generic mfg.
Saphnelo (anifrolumab-fnia) - AstraZeneca
TLR7/9 and type I interferon signaling reprogram neutrophil NET responses and impair antibacterial defense in systemic lupus erythematosus. (PubMed, Cell Press Blue) - Sep 17, 2026 - "In lupus-prone mice, combined hydroxychloroquine (HCQ) and interferon-alpha/beta receptor (IFNAR) blockade restored LDHB expression, rebalanced suicidal and vital NET responses, and improved bacterial clearance. Neutrophils from SLE patients showed similar defects that were reversed by HCQ and the IFNAR-blocking antibody anifrolumab. These findings define an immunometabolic checkpoint linking chronic autoimmune signaling to defective antibacterial defense in SLE and identify therapeutic routes to restore innate immunity." 
IO biomarker • Journal • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • IFNA1 • IFNAR1 • LDHB • TLR7
http://www.ncbi.nlm.nih.gov/pubmed/42746563
 
Andrew J Monteith; Ashley D Wise; Bailey E Holder; Courtney C Lucca; Eden G TenBarge; Ellie C Mennen; Eva Belevska; Helene A Hoover; Helia Esfandiari; Jeffry D Bieber; Jennifer Ferris; Jonathan M Williams; Leslie J Crofford; Morgan L Hetzel; Nicole M Vaccaro; Sarah R McDaniel; Timothy E Sparer
 
Sep 17, 2026
 
Prev Next